QL1209 (pertuzumab Biosimilar) Versus Reference Pertuzumab Plus Trastuzumab and Docetaxel in Neoadjuvant Treatment for HER2-positive, ER/PR-negative, Early or Locally Advanced Breast Cancer: A Multicenter, Randomized, Double-Blinded, Parallel-Controlled, Phase III Equivalence Trial
British Journal of Cancer（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined